PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson’s Disease
December 08, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty...
PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform
December 01, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences...
PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs
November 24, 2020 11:09 ET
|
Newscope Capital Corporation
TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the...
PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform
November 18, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the...
PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer
November 16, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher” or the “Company”) (CSE: PHRM) and a specialty life sciences...
Prolific Parkinson’s Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor
November 11, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...
Leading Parkinson’s Researcher Dr. Robert A. Hauser Joins Pharmather as Scientific Advisor
October 29, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain
October 27, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...
Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals
October 22, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease
October 20, 2020 07:00 ET
|
Newscope Capital Corporation
TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...